Understanding how the immune system's proteasome affects inflammation in lung diseases
Molecular regulation of immunoproteasome assembly in inflammatory diseases
This study is looking at how a part of our immune system called the immunoproteasome affects inflammation during serious bacterial infections, like those that can cause acute respiratory distress syndrome (ARDS), to find new ways to help reduce harmful inflammation and improve treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10878768 on NIH RePORTER |
What this research studies
This research investigates the role of a specific part of the proteasome, known as the immunoproteasome, in the body's inflammatory response to severe bacterial infections, particularly in conditions like acute respiratory distress syndrome (ARDS). The study aims to uncover how the assembly of the immunoproteasome is regulated at a molecular level and how this process contributes to inflammation and tissue damage during infections. By exploring the potential to inhibit the immunoproteasome, the research seeks to identify new therapeutic targets that could help reduce harmful inflammation in patients suffering from severe infections. Patients may benefit from insights that could lead to novel treatments for ARDS and related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients experiencing severe bacterial infections or those diagnosed with acute respiratory distress syndrome.
Not a fit: Patients with non-infectious causes of respiratory distress or those not experiencing significant inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation and improve outcomes for patients with severe bacterial infections and ARDS.
How similar studies have performed: Previous research has shown promise in targeting the immunoproteasome for therapeutic purposes, indicating that this approach may lead to meaningful advancements in treatment.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Zhao, Jing — Ohio State University
- Study coordinator: Zhao, Jing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.